Osteoporosis. NIH Consensus Development
Boletin de la Asociacion Medica de Puerto Rico 77(6): 253-255
1985
ISSN/ISBN: 0004-4849 PMID: 3863632 Document Number: 700584
Document emailed within 1 workday
Related Documents
Spencer, H.; Kramer, L. 1986: NIH Consensus Conference: osteoporosis. Factors contributing to osteoporosis Journal of Nutrition 116(2): 316-319Jolles, B.M.; Bogoch, E.R. 2002: Current consensus recommendations for rheumatoid arthritis therapy: a blind spot for osteoporosis prevention and treatment Journal of Rheumatology 29(9): 1814-1817
Bick, R.L.; Haas, S.K. 1998: International consensus recommendations. Summary statement and additional suggested guidelines. European Consensus Conference, November 1991. American College of Chest Physicians consensus statement of 1995. International Consensus Statement, 1997 Medical Clinics of North America 82(3): 613-633
Lowe, C.U. 1982: Consensus Development: technology assessment at NIH Maryland State Medical Journal 31(1): 55-56
Bernstein, M.J. 1984: National Institutes of Health Consensus Development Program Connecticut Medicine 48(8): 513-515
Hu, D-Yi. 2013: Consensus recommendation on the development of cardiovascular disease polypill in China Zhonghua Xin Xue Guan Bing Za Zhi 41(2): 91-93
Hatae, M.; Onishi, Y.; Maeda, Y.; Nakamura, T.; Maeda, T.; Wada, T. 1995: Consensus and new development in epithelial ovarian cancer chemotherapy in 1995 Gan to Kagaku Ryoho. Cancer and ChemoTherapy 22(9): 1182-1189
Vitali, C.; Bencivelli, W.; Isenberg, D.A.; Smolen, J.S.; Snaith, M.L.; Sciuto, M.; Neri, R.; Bombardieri, S. 1992: Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. The European Consensus Study Group for Disease Activity in SLE Clinical and Experimental Rheumatology 10(5): 541-547
Kahn, D.A.; Docherty, J.P.; Carpenter, D.; Frances, A. 1997: Consensus methods in practice guideline development: a review and description of a new method Psychopharmacology Bulletin 33(4): 631-639
Palencia Herrejón, E.; González Del Castillo, J.; Ramasco Rueda, F.; Candel, F.J.; Sánchez Artola, B.; von Wernitz Teleki, A.; Gordo Vidal, F.; Roces Iglesias, P.; Bejarano Redondo, G.; Rodríguez Serrano, D.A.; Cobo Reinoso, F.J.; Corral Torres, E.; Martí de Gracia, M.; Ruiz Álvarez, A. 2019: Consensus document for sepsis code implementation and development in the Community of Madrid Revista Espanola de Quimioterapia: Publicacion Oficial de la Sociedad Espanola de Quimioterapia 32(4): 400-409
István, L.; Rák, Kálmán.; Losonczy, H.; Blaskó, Görgy. 2003: Conclusions of consensus development conferences on the prevention and treatment of venous thromboembolism Orvosi Hetilap 144(29): 1427-1431
Freeman, J.M. 1981: Consensus statement--febrile seizures: a consensus of their significance, evaluation, and treatment Boletin de la Asociacion Medica de Puerto Rico 73(2): 82
Michel, D. 1988: Consensus with CONSENSUS (Cooperative North Scandinavian Enalapril Survival Study) Fortschritte der Medizin 106(5): 81-82
de Franchis, R.; Hadengue, A.; Lau, G.; Lavanchy, D.; Lok, A.; McIntyre, N.; Mele, A.; Paumgartner, G.; Pietrangelo, A.; Rodés, J.; Rosenberg, W.; Valla, D. 2003: EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version) Journal of Hepatology 39 Suppl. 1: S3-25
Distler, J.H.W.; Jordan, S.; Airo, P.; Alegre-Sancho, J.Jose.; Allanore, Y.; Balbir Gurman, A.; Caporali, R.; Caramaschi, P.; Carreira, P.E.; Chizzolini, C.; Cutolo, M.; Tuncay Duruöz, M.; Farge-Bancel, D.; Hesselstrand, R.; Iannone, F.; De Keyser, F.; Kucharz, E.J.; Launay, D.; García de la Peña Lefebvre, P.; Lukacova, O.; Marasini, B.; Martinovic, D.; Marques Neto, Jão.Francisco.; Radic, M.; Rednic, S.; Riemekasten, G.; Rovensky, J.; Seidel, M.F.; Senel, S.; Smith, V.; Sunderkötter, C.; Ton, E.; van Laar, J.M.; Matucci-Cerinic, M.; Müller Ladner, U.; Distler, O 2011: Is there a role for TNFα antagonists in the treatment of SSc? EUSTAR expert consensus development using the Delphi technique Clinical and Experimental Rheumatology 29(2 Suppl. 65): S40-S45
Gorai, I. 2002: Drugs in development for the treatment of osteoporosis: Tibolone Nihon Rinsho. Japanese Journal of Clinical Medicine 60(Suppl 3): 552-571
Taga, M. 2002: Drugs in development for the treatment of osteoporosis:Raloxifene Nihon Rinsho. Japanese Journal of Clinical Medicine 60(Suppl 3): 572-580
Woodward, A.H.; Jowsey, J. 1974: Estrogens and development of immobilization osteoporosis in rats Surgical Forum 25: 480-481
Ciesielska-Kopacz, N.; Kos-Kudła, B.; Pluskiewicz, W. 1998: The influence of thyroid diseases and their treatment on the development of osteoporosis Przeglad Lekarski 55(5): 271-273
Wynn, R.L. 2000: Osteoporosis, alveolar bone loss, and drug development General Dentistry 48(3): 218-222; 224-225